CS
NGNE icon

Candriam SCA’s Neurogene NGNE Stock Holding History

Candriam SCA’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-39,079
Closed -$805K – 886
2022
Q2 		$805K Hold
39,079
– – 0.01% 665
2022
Q1 		$1.47M Sell
39,079
-3,830
-9% -$223K 0.01% 596
2021
Q4 		$4.14M Hold
42,909
– – 0.03% 393
2021
Q3 		$6.2M Buy
42,909
+17,308
+68% +$2.65M 0.04% 355
2021
Q2 		$4.73M Buy
25,601
+25,599
+1,279,950% +$5.66M 0.03% 415
2021
Q1 		$0 Buy
+2
New +$511 ﹤0.01% 814

Other funds holding NGNE

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Candriam SCA's NGNE Position: Q3 2022 in Review

Candriam SCA sold out of Neurogene (NGNE) in Q3 2022, closing a stake of 39,079 shares — an estimated $805K sold.

Candriam SCA first reported a position in NGNE in Q1 2021 and held it in 6 quarters. The position peaked at $6.2M in Q3 2021. 52 funds tracked by Wall St. Rank hold NGNE as of Q3 2022.

  • Candriam SCA reported no remaining Neurogene position as of Q3 2022 after selling out during the quarter.
  • Candriam SCA sold 39,079 Neurogene shares in Q3 2022, an estimated $805K.
  • Candriam SCA first reported a position in Neurogene in Q1 2021 and held it in 6 quarters.
  • Candriam SCA's Neurogene position peaked at $6.2M in Q3 2021.
  • 52 funds tracked by Wall St. Rank held Neurogene as of Q3 2022.

Based on Candriam SCA's 13F filing for Q3 2022, filed 10 Nov 2022.